RxDoctor Payments Data

Papa Badoe, MD

Internal Medicine · Plainville, MANPI 1659359487

Payments from drug & device makers

$2,887in general payments, 2019–2025

Across 133 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$787
  • AstraZeneca$309
  • Lilly USA, LLC$225
  • Pfizer$211
  • Amgen$119
  • Astellas Pharma US Inc$99
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,79597%
  • Other$933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,887 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$103,612
Medicare patients
270
Services billed
1,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$81,680
TrulicityDulaglutide46$51,750
MounjaroTirzepatide41$49,475
JardianceEmpagliflozin31$47,506
XareltoRivaroxaban39$38,413
JanuviaSitagliptin Phosphate25$29,074
VivitrolNaltrexone Microspheres13$23,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,623
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$17,538
TradjentaLinagliptin17$12,463
Spiriva RespimatTiotropium Bromide23$11,696
Advair HfaFluticasone Propion/Salmeterol16$9,670
SymbicortBudesonide/Formoterol Fumarate40$9,094
Repatha SureclickEvolocumab12$7,682
Combivent RespimatIpratropium/Albuterol Sulfate14$7,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$225$101,22587 claims
PfizerEliquis$211$81,68096 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$91$78,83185 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$88$43,79987 claims
MerckJanuvia$52$29,07425 claims
AstraZenecaSymbicort$309$9,09440 claims
AbbVieSynthroid$23$1,00114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Plainville

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →